4d Molecular Therapeutics(NASDAQ) FDMT

4D Molecular Therapeutics, Inc. makes genetic medicines for serious diseases. It helps people with vision loss and lung problems. These treatments aim to reduce the need for frequent doctor visits.

Engineering Better Health Through Genes

• 4D-150: Experimental treatment for wet age-related macular degeneration and diabetic macular edema; delivered through a single injection into the eye.
• 4D-710: Gene therapy candidate for cystic fibrosis lung disease; designed to deliver functioning genes directly into the lungs of patients.
• 4D-310: Clinical-stage candidate for Fabry disease; targets heart conditions by engineering therapeutic agents to address the underlying genetic cause.
• Therapeutic Vector Evolution: Proprietary technology platform used to design customized delivery vehicles; creates targeted medicines for eye, heart, and lung conditions.

Strategic Moves and Major Partnerships

• Entered a collaboration with Otsuka Pharmaceutical Co., Ltd., in Oct. 2025 to develop and commercialize 4D-150 in various Asia-Pacific markets.
• Secured a $200 million term loan facility from Hercules Capital, Inc., in June 2026 to support clinical trials and ongoing operations.
• Initiated Phase 3 clinical trials, 4FRONT-1 and 4FRONT-2, for wet age-related macular degeneration during 2025.
• Obtained up to $11 million in funding from the Cystic Fibrosis Foundation in Oct. 2025 to advance Phase 2 clinical activities for lung disease.

How the Discovery Process Works

The company uses its proprietary discovery engine to create targeted genetic medicines. This process identifies delivery vehicles that can bypass the body's natural immune defenses to reach specific tissues.

The Numbers Behind the Research

• Research and development expenses rose 50% to $133.3 million for the six-month period ended June 30, 2026.
• Net loss for the six-month period ended June 30, 2026, was $141.7 million, up 38% year over year.
• Cash, cash equivalents, and marketable securities totaled $430.6 million as of June 30, 2026.
• Total collaboration and license revenue reached $6.8 million for the six-month period ended June 30, 2026.
• Accumulated deficit grew to $858.0 million as of June 30, 2026, reflecting the costs of late-stage clinical trials.

Bottom Line

4D Molecular Therapeutics has transitioned from early research to late-stage clinical testing of its lead genetic therapies. Its focus on specialized delivery vehicles and strategic partnerships supports its efforts to address large-market eye and lung diseases.